

Supplementary Table 1 Multivariate analyses of the clinical factors for time to treatment failure replacing m-GPS with PNI

Variables	Multivariate analysis		
	HR	95% CI	<i>P</i> value*
Head in location of tumor	1.26	0.84-1.89	0.266
Metastasis in clinical stage	1.69	1.08-2.66	0.022
CA19-9 \geq 600 U/mL	1.32	0.86-2.04	0.205
PNI < 45	0.77	0.50-1.18	0.227
Sarcopenia	4.70	2.93-7.56	< 0.001

Abbreviations: CA19-9, carbohydrate antigen 19-9; m-GPS, modified Glasgow Prognostic Score; PNI, prognostic nutritional index.

* *P* value of less than 0.05 was considered to be significant.

Supplementary Table 2 Multivariate analyses of the clinical factors for time to treatment failure replacing m-GPS with NLR

Variables	Multivariate analysis		
	HR	95% CI	<i>P</i> value *
Head in location of tumor	1.07	0.70-1.63	0.760
Metastasis in clinical stage	1.83	1.16-2.89	0.009
CA19-9 \geq 600 U/mL	1.27	0.82-1.97	0.275
NLR \geq 2.5	1.47	0.97-2.24	0.068
Sarcopenia	5.19	3.24-8.31	< 0.001

Abbreviations: CA19-9, carbohydrate antigen 19-9; m-GPS, modified Glasgow Prognostic Score; NLR, neutrophil to lymphocyte ratio.

* *P* value of less than 0.05 was considered to be significant.

Supplementary Table 3 Univariate analyses of the potential prognostic factors for overall survival

Variables	Univariate analysis		
	HR	95% CI	<i>P</i> value *
Age \geq 75 years	1.43	0.92-2.22	0.110
Female sex	0.73	0.47-1.12	0.152
BMI < 22.0 kg/m ²	0.74	0.47-1.17	0.193
ECOS PS \geq 2	1.22	0.68-2.17	0.511
Tumor size \geq 30 mm	1.83	1.15-2.93	0.011
Head in location of tumor	1.56	1.02-2.39	0.040
Metastasis in clinical stage	3.02	1.89-4.85	< 0.001
Leukocyte \geq 6.0 $\times 10^3$ /uL	1.40	0.92-2.13	0.121
Neutrophil \geq 4.0 $\times 10^3$ /uL	1.47	0.95-2.70	0.058
Lymphocyte \geq 1.5 $\times 10^3$ /uL	0.92	0.60-1.41	0.700
Platelet \geq 20.0 $\times 10^4$ /uL	1.37	0.89-2.11	0.154
Albumin < 3.5 g/dL	0.48	0.30-0.76	0.002
CRP \geq 1 mg/dL	2.50	1.56-3.99	< 0.001

CA19-9 \geq 600 U/mL	1.80	1.17-2.75	0.007
Total cholesterol <150 mg/dL	0.73	0.46-1.17	0.194
Cholinesterase < 250 IU/L	0.48	1.31-0.74	< 0.001
NLR \geq 2.5	1.50	0.98-2.30	0.064
m-GPS \geq 1	2.41	1.54-3.76	< 0.001
PNI < 45	0.48	0.31-0.75	0.001
Sarcopenia	2.70	1.73-4.20	< 0.001

Supplementary Table 4 Multivariate analyses of the potential prognostic factors for overall survival

Variables	Multivariate analysis		
	HR	95% CI	<i>P</i> value *
Tumor size \geq 30 mm	1.17	0.69-1.98	0.551
Head in location of tumor	1.27	0.81-2.01	0.299
Metastasis in clinical stage	2.25	1.32-3.85	0.003
CA19-9 \geq 600 U/mL	1.52	0.93-2.47	0.091
m-GPS \geq 1	1.98	1.22-3.19	0.005
Sarcopenia	2.89	1.82-4.60	< 0.001

Abbreviations: CA19-9, carbohydrate antigen 19-9; m-GPS, modified Glasgow Prognostic Score.

* *P* value of less than 0.05 was considered to be significant.

Supplementary Table 5 Univariate analyses of the potential prognostic factors for progression-free survival

Variables	Univariate analysis		
	HR	95% CI	<i>P</i> value *
Age \geq 75 years	0.87	0.56-1.36	0.546
Female sex	0.99	0.65-1.51	0.950
BMI < 22.0 kg/m ²	1.23	0.79-1.91	0.358
ECOS PS \geq 2	1.48	0.71-3.09	0.293
Tumor size \geq 30 mm	2.07	1.28-3.34	0.003
Head in location of tumor	1.00	0.66-1.53	0.984
Metastasis in clinical stage	1.94	1.23-3.05	< 0.001
Leukocyte \geq 6.0 $\times 10^3$ /uL	1.21	1.79-1.85	0.382
Neutrophil \geq 4.0 $\times 10^3$ /uL	1.15	0.75-1.78	0.516
Lymphocyte \geq 1.5 $\times 10^3$ /uL	0.93	0.61-1.42	0.741
Platelet \geq 20.0 $\times 10^4$ /uL	0.91	0.59-1.39	0.666
Albumin < 3.5 g/dL	0.71	0.46-1.11	0.136
CRP \geq 1 mg/dL	1.15	0.74-1.79	0.527

CA19-9 \geq 600 U/mL	1.93	1.25-2.99	0.003
Total cholesterol <150 mg/dL	0.79	0.49-1.31	0.377
Cholinesterase < 250 IU/L	1.06	0.67-1.68	0.794
NLR \geq 2.5	1.42	0.92-2.18	0.11
m-GPS \geq 1	1.24	0.81-1.88	0.324
PNI < 45	0.87	0.57-1.34	0.532
Sarcopenia	3.72	2.29-6.01	< 0.001

Supplementary Table 6 Multivariate analyses of the potential prognostic factors for progression-free survival

Variables	Multivariate analysis		
	HR	95% CI	<i>P</i> value *
Tumor size \geq 30 mm	1.32	0.78-2.25	0.300
Metastasis in clinical stage	1.74	1.07-2.85	0.027
CA19-9 \geq 600 U/mL	1.53	0.95-2.47	0.079
Sarcopenia	3.10	1.87-5.12	< 0.001